It is plausible that exogenous hormone exposure due to estrogen and progesterone therapy may affect the regulation of the IGF pathway and thereby modulate germline IGFPB5 variant-related susceptibility to breast cancer. The gene discussed is IGF1; the disease is breast carcinoma.